目的研究胃癌增殖細(xì)胞核抗原(proliferating cell nuclear antigen，PCNA)表達(dá)與腹腔灌洗液端粒酶活性及腹膜轉(zhuǎn)移的相關(guān)性，并比較腹腔灌洗液中端粒酶活性和細(xì)胞學(xué)檢測(cè)游離癌細(xì)胞預(yù)測(cè)腹膜轉(zhuǎn)移的應(yīng)用價(jià)值。
方法應(yīng)用免疫組化SP法檢測(cè)60例胃癌患者胃癌組織中PCNA表達(dá),PCRTRAPELISA法檢測(cè)腹腔灌洗液中端粒酶活性,同時(shí)行腹腔灌洗液脫落細(xì)胞學(xué)(peritoneal lavage cytology,PLC)檢測(cè)； 并分析其與相關(guān)臨床病理因素的關(guān)系。
結(jié)果胃癌患者腹腔灌洗液中端粒酶活性的陽性率為41.7%； 與漿膜侵犯、組織學(xué)類型、浸潤(rùn)深度、漿膜受累面積及腹膜轉(zhuǎn)移密切相關(guān)，并隨著浸潤(rùn)深度及漿膜受累面積的增加而升高(P＜0.05)。PLC檢測(cè)陽性率為25.0%； 在伴肉眼可見腹膜轉(zhuǎn)移灶(P1～3)者明顯增高，也隨著浸潤(rùn)深度及漿膜受累面積的增加而升高。兩種方法檢測(cè)的陽性率總體上差異無統(tǒng)計(jì)學(xué)意義，但在未分化型癌、pT4、伴肉眼可見腹膜轉(zhuǎn)移灶(P1～3)者端粒酶活性陽性率明顯高于PLC。PCNA增殖指數(shù)（PI）在腹腔灌洗液端粒酶活性表達(dá)陽性者明顯高于表達(dá)陰性者，伴肉眼可見腹膜轉(zhuǎn)移灶(P1～3)者明顯高于無肉眼可見腹膜轉(zhuǎn)移灶（P0）者，漿膜受侵者明顯高于漿膜未受侵者（P均＜0.05）。
結(jié)論兩種方法均適用于胃癌腹腔脫落癌細(xì)胞的診斷或腹膜轉(zhuǎn)移的預(yù)測(cè)，端粒酶活性檢測(cè)微量癌細(xì)胞的靈敏度優(yōu)于PLC法檢測(cè)； 胃癌端粒酶活性與惡性增殖活性密切相關(guān)； 胃癌高增殖活性是漿膜受侵及腹膜轉(zhuǎn)移的重要原因。
引用本文： 達(dá)明緒 ,趙紫罡,羅婷,張明鳴,伍曉汀. 胃癌細(xì)胞增殖與腹腔灌洗液中端粒酶活性及腹膜轉(zhuǎn)移的相關(guān)性研究. 中國(guó)普外基礎(chǔ)與臨床雜志, 2006, 13(1): 25-28. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | Lee CC, Lo SS, Wu CW, et al. Peritoneal recurrence of gastric adenocarcinoma after curative resection [Ｊ]. Hepatogastroenterology, 2003; 50(53)∶1720. |
| 2. | Abe S, Yoshimura H, Tabara H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome [Ｊ]. J Surg Oncol, 1995; 59(4)∶226. |
| 3. | Asao T, Fukuda T, Yazawa S, et al. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer [Ｊ]. Cancer, 1991; 68(1)∶44. |
| 4. | Bonenkamp JJ, Songun I, Hermans J, et al. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer [Ｊ]. Br J Surg, 1996; 83(5)∶672. |
| 5. | Shay JW, Bacchetti S. A survey of telomerase activity in human cancer [Ｊ]. Eur J Cancer, 1997; 33(5)∶787. |
| 6. | Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer [Ｊ]. Cancer Res, 1995; 55(15)∶3258. |
| 7. | Maruyama Y, Hanai H, Fujita M, et al. Telomere length and telomerase activity in carcinogenesis of the stomach [Ｊ]. Jpn J Clin Oncol, 1997; 27(4)∶216. |
| 8. | Ahn MJ, Noh YH, Lee YS, et al. Telomerase activity and its clinicopathological significance in gastric cancer [Ｊ]. Eur J Cancer, 1997; 33(8)∶1309. |
- 1. Lee CC, Lo SS, Wu CW, et al. Peritoneal recurrence of gastric adenocarcinoma after curative resection [Ｊ]. Hepatogastroenterology, 2003; 50(53)∶1720.
- 2. Abe S, Yoshimura H, Tabara H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome [Ｊ]. J Surg Oncol, 1995; 59(4)∶226.
- 3. Asao T, Fukuda T, Yazawa S, et al. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer [Ｊ]. Cancer, 1991; 68(1)∶44.
- 4. Bonenkamp JJ, Songun I, Hermans J, et al. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer [Ｊ]. Br J Surg, 1996; 83(5)∶672.
- 5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer [Ｊ]. Eur J Cancer, 1997; 33(5)∶787.
- 6. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer [Ｊ]. Cancer Res, 1995; 55(15)∶3258.
- 7. Maruyama Y, Hanai H, Fujita M, et al. Telomere length and telomerase activity in carcinogenesis of the stomach [Ｊ]. Jpn J Clin Oncol, 1997; 27(4)∶216.
- 8. Ahn MJ, Noh YH, Lee YS, et al. Telomerase activity and its clinicopathological significance in gastric cancer [Ｊ]. Eur J Cancer, 1997; 33(8)∶1309.